We read with great interest the article by Palermo et al. reporting a multicentre real-world experience with recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) for idiopathic inflammatory myositis (IIM) [1]. By summarising outcomes in 26 patients treated for remission induction or maintenance across several Italian tertiary centres, the authors provide timely evidence that hf-SCIg can be a feasible option beyond primary immunodeficiency, with stabilisation of muscle strength, creatine kinase (CK) levels and corticosteroid dose over follow-up.
